In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

Today, Pride is still an uprising. Keeping HIV awareness and prevention at the heart of Pride Month deepens its mission and ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts ...

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.